Fredun Pharmaceuticals Limited (BOM:539730)

Fredun Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	-	649.27	6.37	10.72	29.47	19.38
Short-Term Investments	-	-	45.36	2.41	1.51	1.08
Trading Asset Securities	-	-	-	8.08	3.08	0.58
Cash & Short-Term Investments	649.27	649.27	51.73	21.21	34.05	21.04
Cash Growth	986.97%	1155.15%	143.94%	-37.73%	61.84%	81.16%
Accounts Receivable	-	926.85	1,771	648.49	345.6	902.73
Other Receivables	-	-	-	-	-	0.16
Receivables	-	935.56	1,776	650.95	347.11	903.79
Inventory	-	2,698	2,399	1,750	1,501	464.6
Restricted Cash	-	0.54	0.5	0.38	3.38	0.26
Other Current Assets	-	698.31	45.02	149.49	276.34	136.81
Total Current Assets	-	4,982	4,272	2,572	2,162	1,526
Property, Plant & Equipment	-	1,176	524.89	461.53	386.26	322.82
Long-Term Investments	-	132.18	19.93	4.66	0.03	0.03
Other Intangible Assets	-	6.32	4.27	4.2	3.08	0.56
Other Long-Term Assets	-	124.32	52.98	33.61	21.32	19.98
Total Assets	-	6,421	4,874	3,076	2,573	1,870

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	-	875.83	1,448	629.47	593.43	486.17
Accrued Expenses	-	61.01	60.62	27.98	27.47	24.45
Short-Term Debt	-	-	1,506	867.6	677.09	186.19
Current Portion of Long-Term Debt	-	1,661	69.21	59.52	33.98	-
Current Portion of Leases	-	197.51	12.37	-	-	-
Current Income Taxes Payable	-	95.41	71.16	55.35	42.9	27.91
Other Current Liabilities	-	77.95	113.92	28.36	21.7	12.79
Total Current Liabilities	-	2,969	3,281	1,668	1,397	737.5
Long-Term Debt	-	563.1	96.13	127.98	154.4	420.39
Pension & Post-Retirement Benefits	-	19.43	18.56	11.62	9.97	10.03
Long-Term Deferred Tax Liabilities	-	65.48	44.84	41.37	38.43	14.31
Other Long-Term Liabilities	-	23.13	19.77	12.04	9.67	7.05
Total Liabilities	-	3,640	3,460	1,861	1,609	1,189

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	-	54.73	47.22	46.99	45.32	44.33
Additional Paid-In Capital	-	1,624	727.73	714.27	549.69	454.12
Retained Earnings	-	952.95	628.39	437.73	285.48	180.04
Comprehensive Income & Other	-	149.54	10.5	15.72	83.27	2.13
Total Common Equity	2,781	2,781	1,414	1,215	963.76	680.61
Minority Interest	-	-0	-	-	-	-
Shareholders' Equity	2,781	2,781	1,414	1,215	963.76	680.61
Total Liabilities & Equity	-	6,421	4,874	3,076	2,573	1,870

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	2,422	2,422	1,684	1,055	865.47	606.59
Net Cash (Debt)	-1,772	-1,772	-1,632	-1,034	-831.41	-585.54
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-106.73	-110.88	-117.20	-74.24	-61.89	-47.01
Filing Date Shares Outstanding	5.51	16.42	14.16	14.1	13.6	13.3
Total Common Shares Outstanding	5.51	16.42	14.16	14.1	13.6	13.3
Working Capital	-	2,013	991.06	903.72	765.54	788.99
Book Value Per Share	169.39	169.39	99.81	86.17	70.88	51.18
Tangible Book Value	2,775	2,775	1,410	1,211	960.68	680.05
Tangible Book Value Per Share	169.01	169.01	99.51	85.87	70.65	51.14
Land	-	90.63	5.24	5.24	5.24	5.24
Buildings	-	341.56	220.93	220.93	210.02	210.02
Machinery	-	1,029	501.84	391.07	289.59	198.63

Data Source: S&P Global Market Intelligence Last updated: Aug 5, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 5, 2026

Data Sources Report a data error